Aveanna Healthcare Q4 revenue beats estimates on PDS segment strength

Aveanna Healthcare Holdings

19/03/2026 11:11

((This story was generated using AI and automation, please see
disclaimer https://bit.ly/rtrsnai))
    
    Overview
  
    * U.S. home care provider's Q4 revenue rose 27%, beating analyst expectations
    * Adjusted EBITDA for Q4 climbed 54% yr/yr
    * Company announced agreement to acquire Family First Homecare

    
    Outlook
  
    * Aveanna maintains 2026 revenue guidance of $2.54 bln to $2.56 bln
    * Company maintains 2026 adjusted EBITDA guidance of $318 mln to $322 mln
    * Aveanna says 2026 guidance excludes pending Family First Homecare acquisition

    
    Result Drivers
  
    * SEGMENT GROWTH - Revenue growth driven by increases in PDS, HHH, and MS segments, with PDS contributing the largest share
    * ACQUISITION INTEGRATION - Completion of Thrive Skilled Pediatric Care integration positioned company for further acquisitions

    
Company press release:  ID:nGNXbZLTLc 
    
    Key Details
  
                               
                               
 Metric    Beat/Mis  Actual    Consensu
           s                   s
                               Estimate
                               
                               
 Q4        Beat      $662.50   $645.47
 Revenue             mln       mln (10
                               Analysts
                               )
 Q4 EPS              $0.80      
 Q4 Net              $178.80    
 Income              mln       
 Q4                  $85 mln    
 Adjusted                      
 EBITDA                        
    
    Analyst Coverage
  
    * The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
    * The average consensus recommendation for the healthcare facilities & services peer group is "buy"
    * Wall Street's median 12-month price target for Aveanna Healthcare Holdings Inc is $11.00, about 59.2% above its March 18 closing price of $6.91
    * The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 15 three months ago

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)